JO
ORMP icon

John Overdeck’s Oramed Pharmaceuticals ORMP Stock Holding History

John Overdeck’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-64,418
Closed -$138K – 3434
2025
Q1 		$138K Sell
64,418
-45,960
-42% -$106K ﹤0.01% 2916
2024
Q4 		$267K Sell
110,378
-31,305
-22% -$74.4K ﹤0.01% 2771
2024
Q3 		$346K Sell
141,683
-8,684
-6% -$21.2K ﹤0.01% 2619
2024
Q2 		$386K Buy
150,367
+15,913
+12% +$37.8K ﹤0.01% 2489
2024
Q1 		$393K Sell
134,454
-22,876
-15% -$64K ﹤0.01% 2442
2023
Q4 		$363K Buy
157,330
+125,805
+399% +$269K ﹤0.01% 2615
2023
Q3 		$82.3K Sell
31,525
-28,075
-47% -$88.4K ﹤0.01% 2763
2023
Q2 		$213K Sell
59,600
-446,655
-88% -$1.43M ﹤0.01% 2624
2023
Q1 		$1.1M Buy
+506,255
New +$1.61M ﹤0.01% 1813
2022
Q4 		– Sell
-163,015
Closed -$1.06M – 3005
2022
Q3 		$1.06M Sell
163,015
-476,542
-75% -$3.86M ﹤0.01% 1441
2022
Q2 		$2.93M Buy
639,557
+88,601
+16% +$473K 0.01% 997
2022
Q1 		$4.77M Buy
550,956
+148,859
+37% +$1.53M 0.01% 954
2021
Q4 		$5.74M Buy
+402,097
New +$8.41M 0.01% 1111

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

John Overdeck's ORMP Position: Q2 2025 in Review

John Overdeck sold out of Oramed Pharmaceuticals (ORMP) in Q2 2025, closing a stake of 64,418 shares — an estimated $138K sold.

John Overdeck first reported a position in ORMP in Q4 2021 and held it in 13 quarters. The position peaked at $5.74M in Q4 2021. 47 funds tracked by Wall St. Rank hold ORMP as of Q2 2025.

  • John Overdeck reported no remaining Oramed Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • John Overdeck sold 64,418 Oramed Pharmaceuticals shares in Q2 2025, an estimated $138K.
  • John Overdeck first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 13 quarters.
  • John Overdeck's Oramed Pharmaceuticals position peaked at $5.74M in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2025.

Based on Two Sigma Investments's 13F filing for Q2 2025, filed 14 Aug 2025.